Physician profile
Elliott Snyder
NPI 1881981231
$755.66
in general payments reported to CMS, 2019-2025
12 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.04 · 2020: $72.67 · 2022: $20.18 · 2023: $56.16 · 2024: $218 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $277.11 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $170.60 | 2025 | Idosetr |
| Aerie Pharmaceuticals, INC. | $47.24 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $42.18 | 2023-2024 | Acthar |
| Amgen INC. | $42.03 | 2024-2025 | Tepezza |
| Rxsight INC | $37.46 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Abbvie INC. | $35.92 | 2023 | Lumigan, Alphagan P |
| Allergan, INC. | $27.86 | 2020 | |
| Shire North American Group INC | $24.61 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.18 | 2022 | |
| Alcon Vision LLC | $18.47 | 2024 | Rhopressa |
| Novartis Pharmaceuticals Corporation | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliott Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.